Xenon Pharmaceuticals Inc. (XENE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 15M 30M 45M FY12: 14.3M FY13: 27.4M FY14: 28.4M FY15: 15.6M FY16: 1.8M FY17: 311K FY19: 6.8M FY20: 32.2M FY21: 18.4M FY22: 9.4M FY23: 0 FY24: 0 FY25: 7.5M FY12 FY14 FY16 FY19 FY21 FY23 FY25

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-450M -300M -150M 0 150M 300M 450M FY12: -3.2M FY13: 9.7M FY14: 11.1M FY15: -9.4M FY16: -24.8M FY17: -32.6M FY18: -38M FY19: -42.8M FY20: -31.3M FY21: -79M FY22: -129.1M FY23: -214.1M FY24: -279.3M FY25: -373.1M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-450M -300M -150M 0 150M 300M 450M FY12: -4.3M FY13: 12M FY14: 13M FY15: -15.8M FY16: -23M FY17: -30.7M FY18: -34.5M FY19: -41.6M FY20: -28.8M FY21: -78.9M FY22: -125.4M FY23: -182.4M FY24: -234.3M FY25: -345.9M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-300M -200M -100M 0 100M 200M 300M FY12: 45.6M FY13: -3.3M FY14: 266K FY15: -18.1M FY16: -19.6M FY17: -28.7M FY18: -34.7M FY19: -4.7M FY20: -48.1M FY21: -69.5M FY22: -101M FY23: -151.1M FY24: -181.4M FY25: -279.1M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-300M -200M -100M 0 100M 200M 300M FY12: 45M FY13: -3.5M FY14: -1.3M FY15: -18.7M FY16: -19.8M FY17: -29M FY18: -35.2M FY19: -6M FY20: -50.8M FY21: -71.6M FY22: -103.9M FY23: -156.7M FY24: -184.5M FY25: -279.9M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 30M 60M 90M FY12: 1.3M FY13: 2M FY14: 4M FY15: 14.3M FY16: 15.5M FY17: 18M FY18: 19.4M FY20: 34.5M FY21: 43.6M FY22: 60.5M FY23: 66.9M FY24: 77.9M FY25: 79.3M FY12 FY14 FY16 FY18 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q2 '15: 1.11 Q3 '15: -0.85 Q4 '15: -1.25 Q1 '16: -0.84 Q2 '16: -1.19 Q3 '16: -1.43 Q4 '16: -1.48 Q1 '17: -1.68 Q2 '17: -1.67 Q3 '17: -1.59 Q4 '17: -1.72 Q1 '18: -1.50 Q2 '18: -1.54 Q3 '18: -1.74 Q4 '18: -1.58 Q1 '19: -1.79 Q2 '19: -1.71 Q3 '19: -1.41 Q4 '19: -1.53 Q1 '20: -1.33 Q2 '20: -0.96 Q3 '20: -0.88 Q4 '20: -0.81 Q1 '21: -1.01 Q2 '21: -1.52 Q3 '21: -1.63 Q4 '21: -1.77 Q1 '22: -1.70 Q2 '22: -1.74 Q3 '22: -1.95 Q4 '22: -2.04 Q1 '23: -2.32 Q2 '23: -2.49 Q3 '23: -2.65 Q4 '23: -2.72 Q1 '24: -2.71 Q2 '24: -2.74 Q3 '24: -2.82 Q4 '24: -3.02 Q1 '25: -3.23 Q2 '25: -3.55 Q3 '25: -3.89 Q4 '25: -4.36 Q1 '26: -4.70 Q2 '26: -4.74 Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.